PDS Biotechnology (PDSB) Expected to Announce Quarterly Earnings on Thursday

PDS Biotechnology (NASDAQ:PDSB) will likely be issuing its quarterly earnings data before the market opens on Thursday, March 27th. Analysts expect the company to announce earnings of ($0.31) per share for the quarter.

PDS Biotechnology Price Performance

Shares of NASDAQ PDSB opened at $1.37 on Tuesday. The stock has a market cap of $52.32 million, a PE ratio of -1.18 and a beta of 1.68. The company has a current ratio of 2.84, a quick ratio of 2.84 and a debt-to-equity ratio of 0.55. PDS Biotechnology has a 12-month low of $1.13 and a 12-month high of $4.92. The company has a 50-day moving average of $1.42 and a 200 day moving average of $2.20.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on the company. HC Wainwright restated a “buy” rating and issued a $21.00 price target on shares of PDS Biotechnology in a research report on Thursday, March 13th. B. Riley dropped their target price on PDS Biotechnology from $9.00 to $7.00 and set a “buy” rating for the company in a report on Monday, November 25th. One analyst has rated the stock with a sell rating, three have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $11.67.

About PDS Biotechnology

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.